Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
|
|
- Arline York
- 5 years ago
- Views:
Transcription
1 Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy
2 Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma (MM) Treatment Phases Induction therapy Autograft 1 or 2 Consolidation Maintenance Goals: Maximize the rate and depth of response Minimize residual tumor cells beyond the level of MRD negativity Prevent or delay relapse Increase PFS and OS ultimately: Tailor treatment based on disease characteristics MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival Cavo M, et al. Blood. 2011;117(23): Cavo M, et al. Blood. 2012;120(1):9-19. Kumar S, et al. Lancet Oncol. 2016;17(8):e328-e346.
3 PFS, % Induction Therapy: State of the Art Induction therapy VTD VCD VRD PAD ESMO Guidelines 2017: 3-drug VD-based combinations are the current standard of care for induction therapy. 4-6 courses of induction are recommended prior to peripheral blood stem cell collection Meta-Analysis of Bortezomib-Based Induction vs Non-Bortezomib Time, Months Moreau P, et al. Ann Oncol. 2017;28(suppl_4):iv52-iv61. Sonneveld P, et al. J Clin Oncol. 2013;31(26):
4 Regimens / Study Induction Therapy: State of the Art PAd vs VCD 34.3 vs 37.0 Prospective 1 P =.58 VTD vs VCD 66.3 vs 56.2 Prospective 2 P =.05 VTD vs VCD 64 vs 37 Case-matched 3 P<.001 Which is the best partner for a PI? Response Safety Profile VGPR % CR % SAEs % Grade 3/4 PN % 4.4 vs 8.4 P = vs 8.9 P = vs 6 P< vs 24 P = vs 2.9 P =.05 7 vs 2 P =.009 CR, complete response; PI, proteasome inhibitor; PN, peripheral neuropathy; SAE, serious adverse event; VGPR, very good partial response 1. Mai EK, et al. Leukemia. 2015;29(8): Moreau P, et al. Blood. 2016;127(21): Cavo M, et al. Leukemia. 2015;29(12):
5 Screening Follow-up VTD vs Dara-VTD Induction Therapy CASSIOPEIA Phase III Trial Induction Consolidation Maintenance Arm A VTD 4x VTD 2x Observation until PD (max. 2 years) R ASCT R Subjects with PR or better Arm B VTD + DARA 4x VTD + DARA 2x DARA q 8 weeks until PD (max. 2 years followed by observation until PD) Part 1 Part 2 ASCT, autologous stem cell transplant; DARA, daratumumab; PD, progressive disease; PR, partial response National Institutes of Health. Accessed 5 June 2018.
6 VRD Induction Therapy (6 Cycles) Response Response, n (%) Overall Complete response 176 (39) scr 126 (28) CR 50 (11) VGPR 133 (29) PR 77 (17) MRD-negative* (n = 320) 35% Overall response 386 (85) Toxicity Grade 1 Grade 2 Grade 3 Grade 4 PN/neuropathic pain Neurologic Toxicity 91 (20%) 48 (10%) 14 (3%) 1 (<1%) Outcomes of VTD** Induction x 6 Cycles Complete response (%) 35 Grade 3 PN (%) 14 *NGF 3 x 10-6 *Bortezomib 1.3 mg/m 2 SC (days 1,4,8,11); lenalidomide 25 mg/day PO (days 1-21); dexamethasone 40 mg/day PO (days 1-4,9-12; 28-day cycles) **Bortezomib 1.3 mg/m 2 IV (days 1,4,8,11); talidomide 200 mg/day PO; dexamethasone 40 mg/day PO (days 1-4,9-12; 28-day cycles) Rosiñol L, et al. Blood. 2012;120(8): Rosiñol L, et al. Blood. 2017;130: Abstract 130.
7 Phase II Study: Daratumumab-VRd vs VRd in NDMM Part 1: Safety Run-In (N = 16) Induction (Cycles 1-4) ASCT DARA: 16 md/kg weekly in cycles 1-4 and every 3 weeks in cycles R: 25 mg PO V: 1.3 mg/m 2 SC D: 40 mg PO weekly Maintenance (Cycles 7-32) Consolidation (Cycles 5-6) DARA: 16 md/kg every 8 weeks for cycles R: 10 mg PO daily on days 1-21, then 15 mg PO daily beginning cycle 10 (if no tolerability issues) D: 20 mg PO every 8 weeks Voorhees PM, et al. Blood. 2017;130: Abstract Safety Profile of Patients Treated During Cycles 1-4 N = 16 At least 1 treatment-emergent adverse event TEAE), n (%) 16 (100) Related to daratumumab 14 (88) Most common TEAEs (all grades) occurring in 20% of patients, n (%) Neutropenia 8 (50) Lymphopenia 7 (44) Thrombocytopenia 7 (44) Fatigue 6 (38) Edema peripheral 6 (38) Anemia 5 (31) Constipation 5 (31) Leukopenia 4 (25) Hypoalbuminemia 4 (25) Hypocalcemia 4 (25) Insomnia 4 (25) 2 patients had SAE considered related to daratumumab (gastroenteritis, pneumonitis) 5 patients had a grade 2 IRR
8 Screening VRD vs Elo-VRD Induction Therapy GMMG-HD6 Phase III Trial Induction Consolidation Maintenance VRD VRD Len/Dex VRD VRD + Elotuzumab Len/Dex + Elotuzumab R VRD + Elotuzumab ASCT VRD Len/Dex VRD + Elotuzumab VRD + Elotuzumab Len/Dex + Elotuzumab National Institutes of Health. Accessed 5 June 2018.
9 Patients, % Patients, % Patients, % Carfilzomib and IMiD-Based Induction Therapy KRd + ASCT Phase II (N = 73) 1 KRd + ASCT Phase II IFM (N = 46) 2 KTd + ASCT Phase II (N = 91) 3 Induction KRd x4 Induction KRd x4 Induction KTd x4 a b VGPR CR scr KRd, carfilzomib-lenalidomide-dexamethasone. R, lenalidomide. 1. Jakubowiak A, et al. Haematologica. 2016;101(S1): Abstract S Roussel M, et al. Blood. 2016;128: Abstract Sonneveld P, et al. Blood. 2015;125(3):
10 PBSC Mobilization Response, % KRd vs KCd Induction Therapy Four 28-Day Cycles Arm A: KCd Induction Carfilzomib* + cyclophosphamide + dexamethasone (n = 159) Preliminary Efficacy P =.01 P =.005 Arm B: KRd Induction Carfilzomib* + lenalidomide + dexamethasone Arm C: KRd Induction Carfilzomib* + lenalidomide + dexamethasone *In the current analysis patients randomized to arms B and C were pooled together (n = 318) PBSC, peripheral blood stem cell; ncr, near CR; scr, stringent CR Gay FM, et al. J Clin Oncol. 2017;35((Suppl 4): Abstract Gay F, et al. Blood. 2017;130:Abstract 4541.
11 PFS, Probability PFS Patients, % Upfront ASCT: State of the Art Autograft 1 or 2 ESMO Guidelines 2017: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment in fit patients EMN02/HO95 Phase III Study: VMP vs ASCT IFM 2009 Phase III Study: RVD vs ASCT Median follow-up: 37.8 months Median follow-up: 43.5 months Cavo M, et al. Blood. 2017;130: Abstract 397. Attal M, et al. N Engl J Med. 2017;376(14):
12 OS, Probability OS Patients, % Upfront ASCT: State of the Art Autograft 1 or 2 Though, no OS benefit with auto-transplant was seen in both studies. The follow-up is still too short to justify any delay of autotransplant at the time of relapse EMN02/HO95 Phase III Study: VMP vs ASCT IFM 2009 Phase III Study: RVD vs ASCT HR: 1.00 (95% CI, ), P =.981 HR: 1.16 (95% CI, ), P =.87 HR (95% CI: 1.16 ( ); P = 0.87 Cavo M, et al. Blood. 2017;130: Abstract 397. Attal M, et al. N Engl J Med. 2017;376(14):
13 EMN02/HO95 MM Phase III Trial: Study Design VCD induction x 3-4 cycles + PBSC collection R1 VMP x 4 cycles Bortezomib 1.3 mg/m 2 d 1,4,8,11,22,25,29,32/42 Melphalan 9 mg/m 2 d 1-4/42 Prednisone 60 mg/m 2 d 1-4/42 (497 patients) Melphalan (HDM) 200 mg/m 2 x 1-2 courses* + single or double ASCT (695 patients) R2 VRD consolidation x 2 cycles No consolidation Maintenance lenalidomide Stratification according to center and ISS disease stage (I vs II vs III) Randomization to VMP or HDM was 1:1 in centers with a fixed single ASCT policy Randomization to VMP or HDM-1 or HDM-2 was 1:1:1 in centers with a double ASCT policy Cavo M, et al. Blood. 2017;130: Abstract 401
14 EMN02/HO95 Trial: Randomization patients were eligible for R1 Single ASCT policy Randomization 1:1 Double ASCT policy Randomization 1:1:1 VMP (294 patients) VMP (203 patients) ASCT-1 (280 patients) ASCT-1 (208 patients) ASCT-2 (207 patients) Cavo M, et al. Blood. 2017;130: Abstract 401
15 PFS By Randomization and Cytogenetic Risk ASCT-1 vs ASCT-2 ASCT-1 vs ASCT-2 by High Risk ASCT-2 by Standard or High Risk HR: 0.71 (95% CI, ), P =.040 HR: 0.42 (95% CI, ), P =.014 HR: 0.79 (95% CI, ), P =.483 Cavo M, et al. Blood. 2017;130: Abstract 401
16 OS probability OS By Randomization and Cytogenetic Risk All Patients By High-Risk Cytogenetics % (77.3% ; 93.2%) % (63.6% ; 83.4%) 0.25 HR: 0.51 (95% CI, ), P = ASCT-1 ASCT-2 HR: 0.52 HR: 0.52 (95% (95% CI, CI, ), ), P P=0.042 = Months Number at risk EHA 2018 Oral Presentation, Friday, June 15, ; Abstract S105 (Tacchetti P, et al) Months Cavo M, et al. Blood. 2017;130: Abstract 401
17 STaMINA Phase III Study of Single vs Double ASCT Autograft 1 or 2 The STaMINA study was designed to randomize patients after induction to receive high-dose intensification therapy with Mel-200 and ASCT followed by either lenalidomide maintenance, or VRD consolidation (4 cycles) + lenalidomide maintenance, or a second ASCT + lenalidomide maintenance PFS (ITT Analysis) PFS (High-Risk Patients) Median follow-up 38 months Stadtmauer E, et al. Blood. 2016;128; Abstract LBA1.
18 Consolidation Therapy: State of The Art Consolidation is not yet a standard clinical practice EMN02/HO95 Phase III Study of VRD Consolidation vs No Consolidation PFS by R2 STaMINA Phase III Study of VRD Consolidation vs No Consolidation PFS (ITT analysis) Median follow-up 25 months EHA 2018 Oral Presentation, Friday, June 15, ; Abstract S108 (Sonneveld P, et al) Sonneveld P, et al. Blood. 2016;128: Abstract 242. Stadtmauer E, et al. Blood. 2016;128; Abstract LBA1. Median follow-up 38 months
19 Maintenance Therapy With Lenalidomide ESMO Guidelines 2017: Lenalidomide maintenance is EMA-approved for the treatment of adult patients with newly-diagnosed MM who have undergone ASCT 0.75 ( ).001 Median follow-up 80 months McCarthy PL, et al. J Clin Oncol. 2017;35(29):
20 Lenalidomide Maintenance After ASCT: OS Subgroup Analysis a Number of patients. b Cytogenetic data were available only for the IFM and GIMEMA studies. c CrCl post-asct data were available only for the CALGB and IFM studies. CrCl, creatinine clearance; ISS, International Staging System McCarthy PL, et al. J Clin Oncol. 2017;35(29): Attal M, et al. J Clin Oncol. 2016;34(suppl):Abstract 8001.
21 MYELOMA XI Maintenance With Lenalidomide Transplant Eligible Pathway: PFS Transplant Eligible Pathway: OS HR: 0.48; 95% CI [ ] Log-rank P<.0001 HR: 0.69; 95% CI [ ] Log-rank P =.0130 Jackson GH, et al. Blood. 2016;128: Abstract Jackson GH, et al. J Clin Oncol. 35(Suppl 4): Abstract 8009.
22 OS (%) OS (%) Transplant Eligible Pathway Lenalidomide improved OS irrespective of cytogenetic risk t(4;14) and/or del(17p) absent: HR 0.54 t(4;14) and/or del(17p) present: HR 0.51 Obs Len Median OS [95%CI] Obs. (n=165) NR Len. (n=209) NR Obs Len Median OS [95%CI] Obs. (n=36) 30, [24, Inf.) Len. (n=62) 50, [46, Inf.) HR: %CI [0.26, 1.01] Logrank P = HR: %CI [0.30, 0.98] Logrank P = Est. [95%CI] Est. [95%CI] Obs. (%) 97.5 [ 95.2, 100.0] 88.6 [ 83.4, 94.1] 81.0 [ 74.3, 88.3] 77.2 [ 69.7, 85.5] 73.3 [ 64.7, 83.1] Obs. (%) 78.1 [ 65.0, 93.9] 67.1 [ 52.2, 86.4] 42.4 [ 26.2, 68.7] 42.4 [ 26.2, 68.7] 31.8 [ 15.1, 66.9] Len. (%) 98.0 [ 96.2, 100.0] 96.8 [ 94.3, 99.4] 93.7 [ 89.5, 98.1] 82.5 [ 74.2, 91.7] 75.0 [ 64.4, 87.5] Len. (%) 91.5 [ 84.6, 98.9] 80.6 [ 70.4, 92.4] 69.0 [ 56.1, 84.8] 59.7 [ 44.7, 79.7] 49.7 [ 33.9, 73.0] Time from maintenance randomisation (m) Number at risk Obs Len Time from maintenance randomisation (m) Number at risk Obs Len Jackson GH, et al. Blood. 2017;130: Abstract 436.
23 Maintenance With Bortezomib Lack of phase studies comparing bortezomib vs no bortezomib/placebo Study Details* n Treatment PFS OS HOVON 65 MM / GMMG-HD4 1 Median follow-up: 91.4 months (Overall trial) PAD x 3 HDM bortezomib every 2 weeks for 2 years VAD x 3 HDM Thalidomide daily for 2 years 34 months 28 months; P = % 45%; P =.22 RMST 8 years: 4.8 months; P =.04 PETHEMA/GEM 2 Median follow-up: 58.6 months (From maintenance start) *Bortezomib administered at 1.3 mg/m 2 IV in both studies TV (thal daily, 1 cycle bortezomib every 3 m) for 3 years Thal (daily for 3 years) Interferon- 2b (3 x week for 3 years) 50.6 months 40.3 months 32.5 months; P =.03 Not significantly diffferent between arms 1. Sonneveld P, et al. Blood. 2015;126: Abstract Rosiñol L, et al. Leukemia. 2017;31(9):
24 Current And Future Treatment Algorithm For Transplant-Eligible Patients With MM Until 2017 Ongoing/Planned Induction: 3-drug bort-based tx VTD VCD VRD PAD HDM (200 mg/m 2 ) + ASCT x 1 or 2 Consolidation: 3-drug bort-based tx Induction 3-drug vs 4-drug mab-based tx VTD vs Dara-VTD VRD vs Elo-VRD VTD vs Dara-VCD VRD vs Dara-VRD VRD vs KRD KRD vs Dara-KRD HDM (200 mg/m 2 ) + ASCT x 1 or 2 Consolidation: 3-drug vs 4-drug mab-based tx Maintenance: IMiD-based Maintenance: IMiDs vs PI-lMiDs vs mab-imids vs mab-pis Cavo M, personal communication. Clinicaltrials.gov identifiers: NCT ; NCT ; NCT ; NCT
25 Improvements in Front-Line Therapy for ASCT-Eligible Patients With MM NOVEL AGENTS Induction therapy Autograft 1 or 2 Consolidation Maintenance New drug combinations Cavo M, personal communication. Future Cure myeloma? Trial design with genomic and MRD as treatment drivers
26 Summary Induction therapy followed by ASCT is the standard treatment in fit, newly-diagnosed patients with MM Three-drug combinations including bortezomib and dexamethasone are the current standard of care for induction These triplets might be replaced in the near future by four-drug combinations including a mab combined with a PI and an IMiD Double ASCT improves outcomes, especially in patients with unfavorable cytogenetic abnormalities PFS benefit with consolidation therapy confirmed in the second interim analysis of EMN02/HO95 phase III study Lenalidomide maintenance is EMA-approved for the treatment of patients with newlydiagnosed MM who have undergone ASCT Some patient populations may benefit from alternative maintenance regimens Different treatment strategies for transplant-eligible patients with MM possibly guided by genomics and MRD Cavo M, personal communication.
27
Induction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationIn-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationStato dell arte: dalle opzioni terapeutiche alla strategia terapeutica nel 2017
Stato dell arte: dalle opzioni terapeutiche alla strategia terapeutica nel 2017 Elena Zamagni Istituto di Ematologia Seragnoli Università di Bologna Eligibility for ASCT Yes Induction: 3-drug regimens
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationMultiple Myeloma Transplant and Non-transplant Modalities
Multiple Myeloma Transplant and Non-transplant Modalities Sikander Ailawadhi, MD Associate Professor of Medicine Division of Hematology-Oncology Mayo Clinic, Jacksonville, Florida 15 th Annual Miami Cancer
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationTopics. When to treat? Smoldering vs Symptomatic Choice of Induction regimen Role of HDT Role of consolidation/maintenance
Initial Therapy Sagar Lonial, MD Chair and Professor Department of Hematology and Medical Oncology Chief Medical Officer, Winship Cancer Institute Emory University School of Medicine Topics When to treat?
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI What is the standard? Induction/Transplant/Maintenance UPDATED OS DATA from CALGB 100104 & IFM 2005-02
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationMaking Sense of Myeloma Treatment Advances
Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator:
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Armand J. Quick/William F. Stapp Professor of Hematology Director, Adult Blood and Marrow Transplant Program Froedtert Hospital Medical College
More informationASCO 2017: Myeloma update
ASCO 2017: Myeloma update Jonathan L. Kaufman, MD Associate Professor Department of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Daratumumab + KRd in Newly
More information